
|Videos|July 5, 2021
Pharmacist Medication Insights: for Panzyga for Primary Humoral Immunodeficiency
Author(s)Saro Arakelians, PharmD
Panzyga is indicated for the treatment of primary humoral immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and chronic immune thrombocytopenia.
Advertisement
Panzyga (immune globulin intravenous [Human]-ifas) is indicated for the following:
- For the treatment of adults 18 years of age and older with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability and impairment.
- Primary humoral immunodeficiency (PI) in patients 2 years of age and older.
- Chronic immune thrombocytopenia (ITP) in adults.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First-in-Class Centanafadine for ADHD in Adults and Pediatric Patients
2
Pharmacists Are Critical to SGLT2, GLP-1 Use in CKD
3
World Lung Cancer Day: Pharmacists Are Essential Across Prevention, Screening, and Treatment
4
A Pharmacist's Guide to Probiotics for Preventing Traveler’s Diarrhea
5






































































































